- Home
- INZY vs NKSH Comparison
INZY vs NKSH Comparison
Compare INZY & NKSH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INZY
- NKSH
- Stock Information
- Founded
- INZY 2015
- NKSH 1891
- Country
- INZY United States
- NKSH United States
- Employees
- INZY N/A
- NKSH N/A
- Industry
- INZY Biotechnology: Pharmaceutical Preparations
- NKSH Major Banks
- Sector
- INZY Health Care
- NKSH Finance
- Exchange
- INZY Nasdaq
- NKSH Nasdaq
- Market Cap
- INZY 188.2M
- NKSH 190.8M
- IPO Year
- INZY 2020
- NKSH N/A
- Fundamental
- Price
- INZY $1.36
- NKSH $28.88
- Analyst Decision
- INZY Strong Buy
- NKSH Strong Buy
- Analyst Count
- INZY 8
- NKSH 1
- Target Price
- INZY $17.75
- NKSH $38.00
- AVG Volume (30 Days)
- INZY 1.0M
- NKSH 11.8K
- Earning Date
- INZY 03-11-2025
- NKSH 01-23-2025
- Dividend Yield
- INZY N/A
- NKSH 5.22%
- EPS Growth
- INZY N/A
- NKSH N/A
- EPS
- INZY N/A
- NKSH 1.24
- Revenue
- INZY N/A
- NKSH $44,130,000.00
- Revenue This Year
- INZY N/A
- NKSH N/A
- Revenue Next Year
- INZY N/A
- NKSH $9.78
- P/E Ratio
- INZY N/A
- NKSH $23.39
- Revenue Growth
- INZY N/A
- NKSH N/A
- 52 Week Low
- INZY $1.24
- NKSH $26.00
- 52 Week High
- INZY $7.80
- NKSH $35.00
- Technical
- Relative Strength Index (RSI)
- INZY 29.28
- NKSH 47.64
- Support Level
- INZY $1.35
- NKSH $27.66
- Resistance Level
- INZY $1.62
- NKSH $30.48
- Average True Range (ATR)
- INZY 0.13
- NKSH 1.04
- MACD
- INZY 0.04
- NKSH 0.02
- Stochastic Oscillator
- INZY 32.89
- NKSH 39.48
About INZY Inozyme Pharma Inc.
Inozyme Pharma Incclinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of diseases impacting the vasculature, soft tissue, and skeleton. The company is pursuing the development of therapeutics to address the underlying causes of these debilitating diseases. The company is focused on developing a novel therapy to treat the rare genetic diseases of ENPP1 and ABCC6 Deficiencies. The company product candidate, INZ-701, is a soluble, recombinant, genetically engineered, fusion protein that is designed to correct a defect in a pathway involving ENPP1 and ABCC6 Deficiencies.
About NKSH National Bankshares Inc.
National Bankshares Inc is a bank holding company. It focuses on lending to small and mid-sized businesses and individuals. The types of loans it offers include commercial and agricultural, commercial real estate, construction for commercial and residential properties, residential real estate, home equity, and various consumer loan products. It also operates an insurance and brokerage subsidiary, National Bankshares Financial Services, Inc. The company earns its revenues from interest and fees on loans, non-interest income, and investments.